Since the combined pharmacologic blockade of NEP and AT1-receptor with LCZ696 showed significantly reduced overall mortality in the heart failure trial PARADIGM-HF19, we were especially interested in the involvement of NEP in renal alternative RAS activation. Here, MME is linked to heart failure.